Cyberonics Reports Fiscal 2015 Third Quarter Results

CE Mark approval of VITARIA™ generator for CHF ----- U.S. revenue growth of 9% to $58m ---- Continued strong earnings growth

HOUSTON, Feb. 26, 2015 - Cyberonics, Inc. (CYBX) today announced results for the quarter ended January 23, 2015.

Quarterly highlights¹

Operating results for the third quarter of fiscal 2015 compared to the third quarter of fiscal 2014 and other achievements include:

• Worldwide net sales of $72.1 million, an increase of 9% on an adjusted basis;
• U.S. net sales reached $57.6 million, an increase of 9%, with units increasing by 6%;

Henry Schein Medical to Offer Atossa Genetics' FullCYTE Breast Aspirator

SEATTLE, WA--( Feb 26, 2015) - Atossa Genetics Inc. (NASDAQ: ATOS), the Breast Care Company, announced today that Henry Schein Medical, the U.S. Medical business of Henry Schein, Inc. (NASDAQ: HSIC), will offer its customers the FullCYTE Breast Aspirator. The Atossa FullCYTE Breast Aspirator is used by OB/GYNs, primary care physicians and women's clinics to collect fluid from breasts for subsequent cytological evaluation.

Dr. Steven C. Quay, Chairman, President & CEO of Atossa Genetics, commented, "Working with Henry Schein is an important step forward in making the FullCYTE Breast Aspirator available nationwide. Henry Schein is an industry leader and its multi-channel sales organization allows for expanded reach into multiple market segments within health care for our device. We are thrilled to work with a company such as Henry Schein and believe our arrangement will contribute positively to our upcoming nationwide launch."

Second Sight Announces First Commercial Implants of the Argus® II Retinal Prosthesis System in France

SYLMAR, Calif.-- Second Sight Medical Products, Inc. (EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to provide functional vision to blind patients, today announced that all three of the centers approved to implant the Argus II Retinal Prosthesis System (“Argus II”) under the French Government national healthcare reimbursement program entitled ‘Forfait Innovation’ have successfully completed their first implants in patients with retinitis pigmentosa (RP). Current French implant centers are located in Paris, Bordeaux, and Strasbourg.

Thoratec® Reports Fourth Quarter 2014 Results

- Revenue of $128.0 million for the fourth quarter of 2014
- GAAP net income per diluted share of $0.21, and non-GAAP net income per diluted share of $0.39
- Company establishes 2015 guidance for revenue of $450 million to $460 million and net income per diluted share of $0.60 to $0.70 on a GAAP basis and $1.10 to $1.20 on a non-GAAP basis

PLEASANTON, Calif., Feb. 10, 2015 -- Thoratec Corporation (THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today reported its financial results for the fourth quarter of 2014.

"We were pleased with our results in the fourth quarter, which included sequential improvement in overall market growth and our competitive position," said D. Keith Grossman, President and Chief Executive Officer.  "I am encouraged by initial progress with our recent organizational and execution related initiatives, and by the sales performance across all of our key geographies," he added.